Nkarta
NKTX
Market cap $155M

2.18 USD

+0.12

5.83%

At close Jul 30, 4:00 PM EDT

After hours

2.19

+0.01

0.46%

1 day

5.83%

5 days

-1.36%

1 month

31.33%

3 months

2.83%

6 months

-7.63%

Year to date

-12.80%

1 year

-65.67%

5 years

-91.99%

10 years

-95.45%

About: Nkarta Inc is a clinical-stage biopharmaceutical company pioneering the development of allogeneic, off-the-shelf engineered natural killer (NK) cell therapies. The Company is engaged in leveraging the natural potent power of NK cells to identify and kill abnormal cells and recruit adaptive immune effectors to generate responses that are specific and durable. The company is combining its NK expansion platform technology with proprietary cell engineering technologies to generate an abundant supply of NK cells, engineer enhanced NK cell recognition of therapeutic targets, and improve persistence for sustained activity in the body for the treatment of cancer.

Employees: 157

Healthcare Biotechnology

0

Funds holding %

of 7,323 funds

–

Analysts bullish %

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

27% more repeat investments, than reductions

Existing positions increased: 38 | Existing positions reduced: 30

6% more first-time investments, than exits

New positions opened: 19 | Existing positions closed: 18

0% more funds holding

Funds holding: 112 [Q4 2024] → 112 (+0) [Q1 2025]

0% more funds holding in top 10

Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]

1.37% less ownership

Funds ownership: 88.09% [Q4 2024] → 86.72% (-1.37%) [Q1 2025]

27% less capital invested

Capital invested by funds: $155M [Q4 2024] → $113M (-$41.5M) [Q1 2025]

34% less call options, than puts

Call options by funds: $38K | Put options by funds: $58K

See Fund Rankings

Research analyst outlook

2 Wall Street Analysts provided 1 year price targets over the past 3 months

Low target

$10

359%

upside

Avg. target

$12

450%

upside

High target

$14

542%

upside

2 analyst ratings

2 positive

100%

0 neutral

0%

0 negative

0%

Mizuho Salim Syed	542%upside $14	Outperform Maintained	10 Jun 2025
Needham Gil Blum	359%upside $10	Buy Maintained	15 May 2025

See Analyst Rankings

Financial journalist opinion

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

SOUTH SAN FRANCISCO, Calif., July 23, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the H.C. Wainwright “HCW@Home” Series.

Nkarta to Participate in the H.C. Wainwright “HCW@Home” Series

Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025

Nkarta shares have remained flat since my last review in March, reflecting a wait-and-see market stance. Pipeline updates show steady progress, but no major catalysts have emerged; data readouts are expected in the back half of the year. Financials remain stable, with sufficient cash runway to support ongoing clinical development and operational needs.

Nkarta: Holding Its Support Steady Ahead Of First Data Readouts In 2025

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

SOUTH SAN FRANCISCO, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune disease, today announced the appointment of Shawn Rose, M.D. Ph.D., as its next Chief Medical Officer (CMO) and Head of Research and Development (R&D) starting on June 23, 2025. He replaces David R. Shook, M.D., who will be stepping down from the role to pursue other opportunities in the oncology space.

Nkarta Appoints Shawn Rose Chief Medical Officer & Head of R&D as Company Resets Senior Leadership Role for Autoimmune Focus

Zacks Investment Research

Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade

Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Nkarta (NKTX) Moves to Buy: Rationale Behind the Upgrade

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

Nkarta Inc. NKTX on Wednesday reported a first-quarter loss of 43 cents per share, beating the consensus loss of 44 cents.

Nkarta Downgraded, Analyst Cites Competitive Pressure In Autoimmune Space

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

Enrollment open in investigator-sponsored trial (IST) of NKX019 in myasthenia gravis; Ntrust-1, Ntrust-2, and IST of NKX019 in systemic lupus erythematosus remain open to enrollment Ntrust-1 expanded to include primary membranous nephropathy cohort Lymphodepletion regimen modified across platform to include fludarabine and cyclophosphamide with cyclophosphamide alone remaining available for eligible patients Initial data for NKX019 in multiple autoimmune indications expected in second half of 2025 Cash balance of $351.9 million on March 31, 2025, including cash, cash equivalents and investments, expected to fund operations into 2029 SOUTH SAN FRANCISCO, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies, today reported financial results for the first quarter and year ended March 31, 2025.

Nkarta Reports First Quarter 2025 Financial Results and Corporate Highlights

Zacks Investment Research

Nkarta (NKTX) Upgraded to Buy: Here's Why

Nkarta (NKTX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Nkarta (NKTX) Upgraded to Buy: Here's Why

Nkarta to Participate in an April Investor Conference

SOUTH SAN FRANCISCO, Calif., April 01, 2025 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced its participation in the following investor conference:

Nkarta to Participate in an April Investor Conference

Nkarta: Grinding Lower, Trying To Find Support

Nkarta, Inc. has provided significant pipeline updates, showcasing promising advancements in their innovative cell therapy treatments. A financial overview highlights a robust balance sheet, with sufficient cash reserves to support ongoing research and development activities. Strengths include cutting-edge technology and strategic partnerships, while risks involve clinical trial uncertainties and regulatory hurdles.

Nkarta: Grinding Lower, Trying To Find Support

Nkarta: Betting On The Turnaround

Nkarta's NKX019 shows promise in treating autoimmune diseases, despite a 70% stock drop; strategic restructuring extends financial runway to 2029. Q4 and full-year 2024 earnings reveal significant R&D expenses and a net loss, but a strong cash position of $380.5M. Upcoming clinical data from Ntrust-1 and Ntrust-2 trials are key catalysts; positive results could validate NKX019 and attract investor attention.

Nkarta: Betting On The Turnaround

See News Rankings

Charts implemented using Lightweight Charts™